GHK-Cu (Copper Tripeptide-1): The Copper-Bound Form of GHK

Research summary. GHK-Cu is the copper-bound complex of the naturally occurring tripeptide GHK (Gly-His-Lys). It was identified by Loren Pickart in the 1970s as the bioactive form responsible for many of the regenerative properties attributed to GHK in human plasma. The copper ion is bound at the imidazole nitrogen of the histidine residue and additional coordination sites, producing a stable Cu(II)-tripeptide complex with distinctive blue colouration and a body of pharmacological activity that overlaps with — but extends beyond — the free peptide.

Molecular profile

• Sequence: Gly-His-Lys with bound Cu²⁺
• Molecular formula: C₁₄H₂₃CuN₆O₄ (with associated counterions in commercial preparations)
• Molecular weight: ~340.4 g/mol (peptide + copper, exact mass varies with hydration and counterion)
• PubChem CID: 73587
• CAS Number: 89030-95-5
• Synonyms: Copper tripeptide-1, prezatide copper acetate (when supplied as an acetate salt), Iamin (legacy trade name)

Mechanism of action

GHK-Cu's reported activities reflect a combination of the transcriptional effects associated with the GHK tripeptide and copper-dependent biochemistry. Proposed mechanisms include:

• Activation of fibroblast collagen and ECM synthesis. GHK-Cu stimulates dermal fibroblasts to produce collagen, glycosaminoglycans, proteoglycans, and chondroitin sulfate.
• Wound-bed signalling. GHK-Cu acts as a chemoattractant for fibroblasts, immune cells, and endothelial cells at the site of tissue injury, recruiting the cellular components required for tissue repair.
• Pro-angiogenic activity. Reported upregulation of VEGF and FGF-2 expression supports new blood-vessel formation in the wound bed.
• Anti-inflammatory effects. Reductions in TNF-α and IL-6 production have been described in pulmonary and dermal injury models.
• Antimicrobial activity. GHK-Cu, particularly in combination with selected fatty acids, exhibits activity against bacteria and fungi commonly associated with chronic wound infection.
• Copper-dependent enzymatic support. Copper is a required cofactor for lysyl oxidase, superoxide dismutase, and ceruloplasmin, all of which are involved in tissue repair, antioxidant defence, and ECM cross-linking.

Preclinical research highlights

Dermal wound healing. Mouse studies have reported that GHK-Cu accelerates wound closure by approximately 33% in burn injury models, with associated improvements in granulation tissue formation, fibroblast recruitment, and revascularisation [1].

Diabetic wound research. Clinical observation studies in diabetic patients have reported that addition of GHK-Cu to standard wound-care regimens is associated with substantially improved wound closure rates and reduced infection rates compared with standard care alone. While these reports do not constitute regulatory-grade efficacy data, they have supported continued interest in GHK-Cu as a research adjunct in chronic wound research.

Skin barrier and rejuvenation. Cell-culture and human dermal studies have reported effects on skin elasticity, collagen organisation, and reduction of markers associated with photoaging. These observations underlie the wide use of GHK-Cu in cosmetic formulations.

Pulmonary fibrosis (rodent). Mouse studies of bleomycin-induced pulmonary fibrosis have reported attenuated fibrotic remodelling, reduced TNF-α and IL-6 expression, and preserved alveolar architecture with GHK-Cu administration. Similar findings have been reported in mouse models of acute respiratory distress syndrome (ARDS) [1].

Neuroprotection. Rat studies have explored GHK-Cu in models of cerebral ischaemia and traumatic brain injury, with reported reductions in neuronal apoptosis, attenuated neuroinflammation, and effects on the miR-339-5p/VEGFA axis identified as a potential mechanism for the observed neuronal preservation.

Pain modulation. Rat studies have reported dose-dependent effects on pain-related behaviours, attributed in part to elevation of L-lysine and L-arginine concentrations associated with endogenous analgesic pathways.

Hair growth. Topical GHK-Cu formulations have been studied in animal and human hair-follicle research, with reports of effects on follicle-cycle parameters and reductions in markers of follicular miniaturisation.

Why the copper bond matters

A recurring observation in the GHK literature is that several of the most distinctive activities — particularly those involving ECM cross-linking, antimicrobial activity, and antioxidant pathways — depend on copper. Free GHK and GHK-Cu are not equivalent. In aqueous and physiological conditions, free GHK readily picks up available Cu(II), so studies described as using "GHK" frequently in fact involve some degree of GHK-Cu formation. Researchers should be explicit about which form is supplied and whether copper is provided in the experimental medium.

Current research status

GHK-Cu is widely available as a research peptide, as a regulated cosmetic ingredient (often labelled "copper tripeptide-1" or "prezatide copper acetate"), and historically was studied in formal pharmaceutical development for chronic wound applications under the name Iamin. It is not currently approved as a prescription pharmaceutical for any indication. Active research includes:

• Wound healing and chronic ulcer research
• Dermatologic and hair-follicle research
• Pulmonary and CNS preclinical models
• Mechanistic studies of copper-dependent peptide pharmacology

Key takeaways for researchers

• GHK-Cu is the copper-bound form of the naturally occurring tripeptide GHK, with a stable Cu(II)-imidazole-nitrogen coordination centre.
• Reported activities span tissue repair, angiogenesis, antimicrobial activity, anti-inflammation, and neuroprotection.
• Many of GHK-Cu's distinctive activities depend on the copper component; free GHK and GHK-Cu should not be treated as interchangeable.
• It is widely used in cosmetic formulations and as a research peptide, but is not an approved prescription pharmaceutical.

References

1. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 2018;19(7):1987.

---

This article is provided for educational and research purposes only. GHK-Cu is a research peptide. It is not an approved drug or prescription therapeutic agent and is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease or condition. All work involving this peptide should be conducted by qualified personnel within an appropriate research setting and in compliance with applicable institutional and regulatory requirements.